Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
| Title | Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. |
| Publication Type | Journal Article |
| Year of Publication | 2013 |
| Authors | Koiou, E., Tziomalos K., Katsikis I., Delkos D., Tsourdi E. A., & Panidis D. |
| Journal | Hormones (Athens) |
| Volume | 12 |
| Issue | 4 |
| Pagination | 559-66 |
| Date Published | 2013 Oct-Dec |
| ISSN | 1109-3099 |
| Keywords | Adolescent, Adult, Androgens, Anti-Obesity Agents, Comorbidity, Cyclobutanes, Diet, Reducing, Drug Therapy, Exercise, Female, Humans, Hypoglycemic Agents, Lactones, Metformin, Obesity, Overweight, Plasminogen Activator Inhibitor 1, Polycystic Ovary Syndrome, Treatment Outcome, Young Adult |
| Abstract | OBJECTIVE: Polycystic ovary syndrome (PCOS) is characterized by obesity and insulin resistance (IR), which result in elevated plasminogen activator inhibitor-1 (PAI-1) levels. We aimed to assess the changes in PAI-1 levels in PCOS during treatment with metformin and during weight loss.DESIGN: Twenty-three normal weight women with PCOS were given metformin 850 mg bid for 6 months. Fifty overweight/obese women with PCOS were prescribed an energy-restricted diet, were instructed to exercise and were randomized to orlistat 120 mg tid or sibutramine 10 mg qd for 6 months.RESULTS: In normal weight women, treatment with metformin reduced the body mass index (BMI) and circulating androgens, improved markers of IR and lowered PAI-1 levels. In overweight/obese women, sibutramine and orlistat yielded comparable reductions in BMI and markers of IR. In contrast, the effects on the free androgen index (FAI) differed (p=0.027): sibutramine reduced the FAI (p=0.005), whereas orlistat had no effect. The effects of sibutramine and orlistat on PAI-1 levels also differed (p=0.042): sibutramine reduced PAI-1 levels (p<0.001), whereas orlistat had no effect.CONCLUSIONS: Metformin and sibutramine, but not orlistat, reduce PAI-1 levels in PCOS. The reduction in circulating androgens during metformin and sibutramine treatment might be implicated in this decline. |
| Alternate Journal | Hormones (Athens) |
| PubMed ID | 24457404 |
